Objective: We studied the efficacy of teneligliptin in elderly type 2 diabetes patients with renal insufficiency who used linagliptin previously. Methods: We collected retrospectively 50 patients with type 2 diabetes who were ≥ 60 years old and had chronic Kidney disease (CKD-EPI < 90 mL/min/1.73㎡) and were previously treated with linagliptin and switched to teneligliptin after linagliptin cessation. Fasting blood glucose (FBG), 2 hour postprandial blood glucose (PPG), HbA1c, lipid profile and kidney function were evaluated at before and 3 months after teneligliptin treatment. Results: The mean age of study subjects was 73.1 ± 7.3 years and the mean duration of diabetes was 16.7 ± 10.1 years. The mean CKD-EPI was 52.3 ± 22.1 mL/min/1.73㎡. After 3 month follow-up, switch to teneligliptin therapy showed a significant decrease in HbA1c from 8.1 ± 1.4% to 7.8 ± 1.5% (P = 0.002). FBG and PPG reduced significantly (P = 0.017 and P = 0.023, respectively). In addition, teneligliptin showed a tendency to improve lipid profile without statistical significance. Kidney function evaluated using CKD-EPI was not changed with 3 month teneligliptin treatment (52.3 ± 22.1 mL/min/1.73㎡ to 52.7 ± 22.7 mL/min/1.73㎡, P = 0.785). Conclusion: Switch from linagliptin to teneligliptin in elderly type 2 diabetes patients with chronic renal insufficiency showed improved hyperglycemia and dyslipidemia without worsening of eGFR. Teneligliptin was well tolerated in this patient group.